Chapter 391: Hypopituitarism¶
Chapter 391 | Part 12: Endocrinology and Metabolism
KEY CLINICAL POINTS¶
- Hypopituitarism results from impaired production of anterior pituitary hormones, with causes including developmental defects, tumors, trauma, and autoimmune/inflammatory processes.
- Clinical features vary by hormone deficiency, including growth retardation, hypogonadism, hypothyroidism, and adrenal insufficiency, with complications like cardiovascular disease and metabolic disturbances.
- Diagnosis requires biochemical testing (e.g., insulin tolerance test, CRH stimulation) and imaging, with hormone replacement therapy tailored to individual deficiencies.
- Long-term management involves monitoring IGF-1 levels, adjusting dosages during stress, and addressing complications like osteoporosis and cardiovascular risk.
- Genetic mutations (e.g., HESX1, PROP1) and acquired causes (e.g., pituitary apoplexy, radiation) are critical in differential diagnosis.
1. DEFINITION & OVERVIEW¶
Hypopituitarism refers to deficient production of one or more anterior pituitary hormones, leading to clinical manifestations such as growth failure, hypogonadism, hypothyroidism, and adrenal insufficiency. It can be developmental (genetic) or acquired (trauma, tumors, inflammation).
Table 391-1: Etiology of Hypopituitarism¶
| Category | Causes |
|---|---|
| Developmental | Midline cerebral defects, pituitary dysplasia, congenital hypothalamic disorders |
| Traumatic | Head injury, surgical resection, radiotherapy |
| Neoplastic | Pituitary adenoma, craniopharyngioma, metastases |
| Inflammatory | Lymphocytic hypophysitis, sarcoidosis, hemochromatosis |
| Genetic | Mutations in HESX1, PROP1, NR5A1, etc. |
1.1 Etiology¶
Developmental causes include midline defects (e.g., septo-optic dysplasia), genetic mutations (e.g., HESX1, PROP1), and congenital hypothalamic disorders. Acquired causes include tumors (adenoma, craniopharyngioma), trauma, radiation, infections (e.g., tuberculosis, sarcoidosis), and autoimmune processes (e.g., lymphocytic hypophysitis).
1.2 Pathophysiology¶
Defective pituitary development or damage disrupts hormone synthesis/secretion. Genetic mutations affect transcription factors (e.g., SOX2, LHX3) and cell lineage-specific genes (e.g., Pit-1, Prop-1). Acquired damage (e.g., tumors, trauma) causes mass effect or inflammation, leading to hormone deficiency.
2. EPIDEMIOLOGY¶
Acquired hypopituitarism is more common in adults, with risk factors including pituitary tumors, trauma, and radiation. Developmental causes are rare but associated with genetic syndromes (e.g., Prader-Willi, Kallmann syndrome). Incidence is estimated at 1-2 per 100,000, with higher prevalence in patients with pituitary tumors or head trauma.
2.1 Demographics¶
More common in adults, with increased risk in patients with prior cranial irradiation, pituitary tumors, or head trauma. Congenital forms are associated with genetic syndromes and midline defects.
3. ETIOLOGY & PATHOPHYSIOLOGY¶
Genetic mutations (e.g., HESX1, PROP1) disrupt pituitary development, while acquired causes (tumors, trauma, inflammation) damage pituitary tissue. Mutations in transcription factors (e.g., Pit-1, Prop-1) lead to combined hormone deficiencies. Autoimmune processes (e.g., lymphocytic hypophysitis) and infections (e.g., tuberculosis) also contribute.
Table 391-2: Tests of Pituitary Sufficiency¶
| Hormone | Test | Blood Samples | Interpretation |
|---|---|---|---|
| GH | Insulin tolerance test | –30, 0, 30, 60, 120 min for glucose and GH | Glucose <40 mg/dL; GH >3 mg/L |
| ACTH | Insulin tolerance test | –30, 0, 30, 60, 90 min for glucose and cortisol | Cortisol increase >7 mg/dL or >20 mg/dL |
| TSH | TRH test | 0, 20, 60 min for TSH and PRL | TSH increase >5 mU/L |
| LH/FSH | GnRH test | 0, 30, 60 min for LH and FSH | LH increase >10 IU/L, FSH >2 IU/L |
3.1 Genetic Causes¶
Mutations in HESX1, SOX2, LHX3, NR5A1, and others cause developmental defects. Pit-1 mutations lead to GH, PRL, and TSH deficiencies. PROP1 mutations cause combined GH, PRL, T3, and gonadotropin deficiencies.
3.2 Acquired Causes¶
Tumors (adenoma, craniopharyngioma), trauma, radiation, infections (e.g., tuberculosis, sarcoidosis), and autoimmune processes (e.g., lymphocytic hypophysitis) are major acquired causes. Pituitary apoplexy (hemorrhage/infarction) is a common acute cause.
4. CLINICAL FEATURES¶
Symptoms vary by hormone deficiency: growth retardation, hypogonadism, hypothyroidism, and adrenal insufficiency. Complications include cardiovascular disease, osteoporosis, and metabolic disturbances. Severe cases may present with hypoglycemia, hypotension, or CNS hemorrhage.
4.1 Growth and Development¶
Children: Growth failure, delayed puberty, short stature. Adults: Abnormal body composition, reduced muscle mass, and increased visceral fat. Delayed bone age in children suggests hormonal deficiency.
4.2 Endocrine Manifestations¶
Hypothyroidism (weight gain, fatigue), adrenal insufficiency (fatigue, hypotension), hypogonadism (infertility, sexual dysfunction), and GH deficiency (reduced exercise capacity, metabolic issues).
5. DIFFERENTIAL DIAGNOSIS¶
Pituitary tumors, other endocrine disorders (e.g., primary adrenal insufficiency), and genetic syndromes (e.g., Kallmann syndrome, Prader-Willi). Distinguish from hypothalamic dysfunction and other causes of hypogonadism.
5.1 Genetic Syndromes¶
Kallmann syndrome (GnRH deficiency), Prader-Willi syndrome (hypogonadism, obesity), Bardet-Biedl syndrome (hypogonadism, retinal degeneration).
6. INVESTIGATIONS & DIAGNOSIS¶
Biochemical tests (e.g., insulin tolerance, CRH stimulation) and imaging (MRI) are critical. Provocative tests assess pituitary reserve. IGF-1 levels help confirm GH deficiency. MRI identifies structural abnormalities.
Table 391-3: Hormone Replacement Therapy for Adult Hypopituitarism¶
| Hormone Deficit | Hormone Replacement |
|---|---|
| ACTH | Hydrocortisone (10–20 mg/d), Prednisone (5 mg a.m.) |
| TSH | Levothyroxine (0.075–0.15 mg daily) |
| FSH/LH | Testosterone (gel, patch, enanthate) or estrogen/progesterone |
| GH | Somatotropin (0.1–1.25 mg SC qd) |
6.1 Laboratory Tests¶
Measure target organ hormones (e.g., free T4, testosterone) and pituitary hormones (e.g., TSH, ACTH). Insulin tolerance test for GH and ACTH reserve. CRH stimulation for ACTH.
6.2 Imaging¶
MRI to detect pituitary masses, empty sella, or structural defects. CT for acute hemorrhage (pituitary apoplexy).
7. MANAGEMENT & TREATMENT¶
Hormone replacement therapy (e.g., glucocorticoids, thyroid hormone, sex steroids, GH) is essential. Dose adjustments are needed during stress, surgery, or pregnancy. Long-term monitoring for complications (e.g., osteoporosis, cardiovascular risk).
Table 391-4: Features of Adult Growth Hormone Deficiency¶
| Clinical | Imaging | Laboratory |
|---|---|---|
| Impaired quality of life, body composition changes | Pituitary mass/structural damage | Evoked GH <3 ng/mL |
| Reduced exercise capacity, cardiovascular risk | Bone: reduced mineral density | IGF-1 and IGFBP-3 low or normal |
7.1 Hormone Replacement¶
Glucocorticoids (hydrocortisone, prednisone), thyroid hormone (levothyroxine), sex steroids (testosterone, estrogen/progesterone), and GH (0.02–0.05 mg/kg/day in children).
7.2 Monitoring¶
Regular IGF-1, cortisol, and target organ hormone levels. Adjust doses during stress or illness. Use medical alert bracelets for adrenal insufficiency.
8. PROGNOSIS & COMPLICATIONS¶
Long-term mortality risk is 3x higher in adults due to cardiovascular disease. Complications include osteoporosis, metabolic syndrome, and hypoglycemia. Untreated hypopituitarism leads to progressive hormonal insufficiency and severe complications.
8.1 Cardiovascular Risk¶
GH deficiency increases atherosclerosis, hypertension, and left ventricular dysfunction. Adrenal insufficiency contributes to hypotension and hypoglycemia.
9. SPECIAL CONSIDERATIONS¶
Pregnancy requires careful monitoring of hormone replacement. Children need GH therapy to prevent growth failure. Elderly patients require lower GH doses. Genetic counseling is essential for familial syndromes.
9.1 Pregnancy¶
Adjust hormone doses (e.g., higher glucocorticoids, thyroid hormone). Monitor for adrenal insufficiency and fetal growth.
9.2 Pediatrics¶
GH replacement (0.02–0.05 mg/kg/day) is critical for growth. Monitor IGF-1 levels and adjust doses based on bone age.
10. KEY POINTS & CLINICAL PEARLS¶
- Hypopituitarism requires comprehensive hormone replacement and lifelong monitoring. 2. Provocative tests (e.g., insulin tolerance) are essential for diagnosis. 3. Genetic causes (e.g., PROP1 mutations) must be considered in syndromic cases. 4. Adrenal insufficiency is a life-threatening emergency requiring immediate glucocorticoid replacement. 5. GH deficiency in adults is associated with increased cardiovascular risk and metabolic disturbances.